<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-112520" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bismuth Subsalicylate</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Budisak</surname>
            <given-names>Patrick</given-names>
          </name>
          <aff>Virginia Commonwealth University&#x02019;s School of Dentistry</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abbas</surname>
            <given-names>Malak</given-names>
          </name>
          <aff>Corewell Health</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Budisak declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Malak Abbas declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>4</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-112520.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This educational&#x000a0;activity focuses on bismuth subsalicylate's applications in managing gastrointestinal discomfort and traveler's diarrhea. The drug's mechanism of action, potential adverse reactions, and contraindications will be discussed. By also exploring bismuth subsalicylate's pharmacokinetics, optimal administration methods, and necessary monitoring protocols, this program aims to enhance professionals' proficiency in clinical toxicology related to the medication. The goal of this program is to furnish healthcare professionals with the requisite expertise to administer bismuth subsalicylate optimally. By providing evidence-based information, this&#x000a0;discussion facilitates informed decision-making, enabling practitioners to tailor treatment strategies to individual patient needs.&#x000a0;By understanding bismuth subsalicylate's intricacies, healthcare professionals can mitigate adverse reactions, optimize dosages, and deliver precise, safe, and individualized care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Evaluate&#x000a0;the mechanism of action of bismuth subsalicylate.</p></list-item><list-item><p>Assess&#x000a0;the potential adverse effects of bismuth subsalicylate.</p></list-item><list-item><p>Identify&#x000a0;the appropriate monitoring for patients using bismuth subsalicylate.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from&#x000a0;bismuth subsalicylate therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=112520&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=112520">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-112520.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Bismuth subsalicylate (BSS) has been&#x000a0;available to the public for more than 100 years and was first FDA-approved in 1939. BSS was created before widespread hygiene and sanitation practices to cure cholera infections.&#x000a0;This medication&#x000a0;has provided healthcare professionals with an alternative option to antimicrobials for the treatment of nausea and diarrhea. The primary indications of BSS&#x000a0;include&#x000a0;gastrointestinal conditions and traveler's diarrhea.<xref ref-type="bibr" rid="article-112520.r1">[1]</xref></p>
        <p>
<bold>Diarrhea/Dyspepsia</bold>
</p>
        <p>The FDA-approved indications of BSS&#x000a0;include&#x000a0;diarrhea, heartburn, indigestions, nausea, and stomach upset. BSS is effective in situations where patients are experiencing mild gastrointestinal discomfort, as it reduces the severity and incidence of flatulence and diarrhea.<xref ref-type="bibr" rid="article-112520.r2">[2]</xref>&#x000a0;Compared to placebo, BSS was able to provide greater and faster relief in patients with mild, moderate, and severe symptoms.<xref ref-type="bibr" rid="article-112520.r3">[3]</xref> BSS can be&#x000a0;purchased over the counter and does not require a prescription; it has become a preferred self-treatment option for mild diarrhea, replacing the need for an antimicrobial.<xref ref-type="bibr" rid="article-112520.r4">[4]</xref><xref ref-type="bibr" rid="article-112520.r5">[5]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>
<bold> Helicobacter Pylori&#x000a0;</bold>
</p>
        <p>One off-label indication for BSS is the management of&#x000a0;<italic toggle="yes">Helicobacter pylori</italic> (<italic toggle="yes">H. pylori</italic>) gastrointestinal tract infection.<xref ref-type="bibr" rid="article-112520.r6">[6]</xref><xref ref-type="bibr" rid="article-112520.r7">[7]</xref><xref ref-type="bibr" rid="article-112520.r8">[8]</xref>&#x000a0;Studies have shown that when used as part of a quadruple therapy regimen containing a proton pump inhibitor, tetracycline, and metronidazole, BSS eradicated up to 90% of <italic toggle="yes">H. pylori</italic> infections.<xref ref-type="bibr" rid="article-112520.r8">[8]</xref><xref ref-type="bibr" rid="article-112520.r9">[9]</xref>&#x000a0;The American Gastroenterological Association (AGA) suggests bismuth quadruple therapy as a first-line treatment option. This therapy is&#x000a0;administered for 10 to 14 days and includes a proton pump inhibitor (PPI), bismuth, tetracycline, and nitroimidazole. This therapy combination is recommended for patients with previous macrolide exposure or who are allergic to penicillin.<xref ref-type="bibr" rid="article-112520.r9">[9]</xref></p>
        <p>
<bold>Traveler's Diarrhea</bold>
</p>
        <p>Another off-label indication for BSS is prophylaxis and treatment of traveler's diarrhea. In developing countries, traveler's diarrhea affects&#x000a0;more than 50% of tourists.<xref ref-type="bibr" rid="article-112520.r4">[4]</xref> BSS demonstrated effectiveness in the acute treatment of traveler's diarrhea in patients with mild symptoms.<xref ref-type="bibr" rid="article-112520.r10">[10]</xref> A review article that included&#x000a0;4&#x000a0;studies with a combined 2,500 patients found that BSS was significantly superior to placebo for treating travelers' diarrhea. Additionally, BSS decreased stool frequency and time to symptom relief compared to placebo.<xref ref-type="bibr" rid="article-112520.r11">[11]</xref></p>
        <p>BSS may also be used to prevent traveler's diarrhea. However, its prophylactic efficacy was less than antimicrobials (62% versus 80%, respectively).<xref ref-type="bibr" rid="article-112520.r12">[12]</xref> The frequency of administering BSS in multiple doses (3 to&#x000a0;4 times daily) may&#x000a0;decrease patient adherence and affect prevention rates of traveler's diarrhea. Although uncommon, bismuth subsalicylate has also demonstrated effectiveness in the treatment of cholera in children.<xref ref-type="bibr" rid="article-112520.r13">[13]</xref></p>
        <p>For individuals diagnosed with symptomatic microscopic colitis who cannot undergo budesonide therapy, the American Gastroenterological Association (AGA) recommends treatment with bismuth salicylate as an alternative to no treatment, with the goal of inducing clinical remission.<xref ref-type="bibr" rid="article-112520.r14">[14]</xref></p>
      </sec>
      <sec id="article-112520.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Bismuth subsalicylate (BSS) exhibits many properties due to its formulation as an insoluble salt of salicylic acid and trivalent bismuth. The mechanism of action through which BSS works is complex. In the stomach, BSS hydrolyzes into&#x000a0;2 compounds, bismuth and salicylic acid.<xref ref-type="bibr" rid="article-112520.r15">[15]</xref> The salicylate compound is almost completely absorbed into the bloodstream, while bismuth salt is minimally absorbed.<xref ref-type="bibr" rid="article-112520.r16">[16]</xref> The bismuth that remains in the gastrointestinal tract forms other bismuth salts. These bismuth salts contain bactericidal and antimicrobial activity and prevent bacteria from binding and growing on the mucosal cells of the stomach. This is the mechanism by which BSS helps eradicate <italic toggle="yes">H. pylori</italic>.<xref ref-type="bibr" rid="article-112520.r15">[15]</xref> Furthermore, preventing bacterial binding to the mucosal cells provides many benefits, including preventing intestinal secretion, promoting fluid absorption, reducing inflammation, and promoting the healing of any present ulcer in the stomach.<xref ref-type="bibr" rid="article-112520.r17">[17]</xref></p>
        <p>BSS does not appear to alter the normal flora of the stomach. However, its antimicrobial and antisecretory properties play a significant role in combating diarrhea. The antidiarrheal effect of BSS is most likely due to:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>The reduction in prostaglandin formation, as BSS inhibits cyclooxygenase. Prostaglandin induces inflammation and hypermotility.</p>
          </list-item>
          <list-item>
            <p>The stimulation of reabsorption of fluids, sodium, and chloride; this action helps decrease fluid loss.<xref ref-type="bibr" rid="article-112520.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>The inhibition of intestinal secretions&#x000a0;</p>
          </list-item>
        </list>
        <p>In peptic ulcer disease, the likely mechanism of BSS involves its cytoprotective and demulcent activity. In <italic toggle="yes">H. pylori</italic>&#x000a0;infections, BSS blocks the adhesion of the bacteria to the gastric epithelial cells. Additionally, BSS inhibits <italic toggle="yes">H. pylori</italic>'s enzyme activities, including phospholipase, protease, and urease.<xref ref-type="bibr" rid="article-112520.r19">[19]</xref><xref ref-type="bibr" rid="article-112520.r20">[20]</xref></p>
      </sec>
      <sec id="article-112520.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Bismuth subsalicylate is administered orally and requires storage at room temperature. BSS is available in suspension (262 mg/15 mL, 525 mg/15 mL, 525 mg/30 mL) or tablet form&#x000a0;(chewable&#x000a0;tablets 262 mg). Patients (adults and children) should be advised to shake the suspension well before use and to utilize the enclosed dosage cup. The chewable tablets may be dissolved in the mouth or chewed and swallowed. However, non-chewable tablets should be swallowed whole and taken with water. The proper recommended dosage depends on the indication and the age of the patient. Data for BSS use in pediatric patients&#x000a0;younger than 12 years old is limited.</p>
        <p>
<bold>Diarrhea/Dyspepsia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adult dose: 524 mg every 30 min to 1 hr as needed (regular strength) or 1050 mg every 60 min (maximum strength) for up to 2 days (maximum dose of approximately 4,200 mg)</p>
          </list-item>
          <list-item>
            <p>Pediatric dose:
<list list-type="bullet"><list-item><p>Older than 12 years: same as adult dosing &#x000a0;</p></list-item><list-item><p>9 to 12 years: 262 mg every 30 min to 1 hr, as needed&#x000a0;</p></list-item><list-item><p>6 to 9 years: 175 mg every 30 min to 1 hr, as needed</p></list-item><list-item><p>3 to 6 years: 87 mg every 30 min to 1 hr, as needed&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Helicobacter Pylori&#x000a0;</bold>
<xref ref-type="bibr" rid="article-112520.r21">[21]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adult dose (off-label use): 300 mg&#x000a0;4 times daily, as part of quadruple combination therapy for 10 to 14 days&#x000a0;<xref ref-type="bibr" rid="article-112520.r9">[9]</xref><xref ref-type="bibr" rid="article-112520.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Pediatric dose (off-label use): 4 mg/kg twice daily for 10 to 14 days as part of a triple or quadruple therapy&#x000a0;<xref ref-type="bibr" rid="article-112520.r22">[22]</xref><xref ref-type="bibr" rid="article-112520.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Traveler's Diarrhea</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Prophylaxis for traveler's diarrhea adults dose (off-label use): 524 mg&#x000a0;4 times daily with meals and at bedtime during the time of risk (recommendation is limited for trips less than&#x000a0;2 weeks of duration)&#x000a0;<xref ref-type="bibr" rid="article-112520.r23">[23]</xref><xref ref-type="bibr" rid="article-112520.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of traveler's diarrhea adult dose: 524 mg every 30 min to 1 hr as needed (maximum of 8 doses/24 hr)&#x000a0;<xref ref-type="bibr" rid="article-112520.r25">[25]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> No recommendations are&#x000a0;provided according to the manufacturer's label.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>There are no recommendations provided on the drug label. Since salicylates can worsen renal function in patients depending on prostaglandins to maintain GFR, toxicity may occur at lower doses. Using the lowest effective dose for bismuth subsalicylate in the shortest possible period is recommended when clinically feasible.<xref ref-type="bibr" rid="article-112520.r26">[26]</xref></p>
        <p><bold>Pregnancy considerations:</bold> The CDC recommends against using BSS to prevent or treat&#x000a0;traveler's diarrhea in pregnant&#x000a0;women.&#x000a0;</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Given the potential for the infant to absorb salicylate from breast milk, it's advisable to explore alternative treatment options for BSS.<xref ref-type="bibr" rid="article-112520.r27">[27]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;Limited data is available for BSS use in children&#x000a0;younger than 12, and other treatment options may be preferable. Adult dose recommendations are applicable for patients 12 years old or older.</p>
        <p><bold>Older&#x000a0;patients:</bold> No specific recommendations are provided.</p>
      </sec>
      <sec id="article-112520.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Common adverse effects associated with administering bismuth subsalicylate&#x000a0;include nausea, bitter taste, diarrhea, and dark/black stools.<xref ref-type="bibr" rid="article-112520.r28">[28]</xref> Although not common, bismuth toxicity can result from the overconsumption of bismuth subsalicylate over an extended period and can result in the blackening of the tongue and teeth, fatigue, mood changes, and deterioration of mental status.<xref ref-type="bibr" rid="article-112520.r29">[29]</xref>&#x000a0;</p>
        <p>Bismuth subsalicylate can lead to neurotoxicity and&#x000a0;be fatal in rare circumstances.<xref ref-type="bibr" rid="article-112520.r30">[30]</xref><xref ref-type="bibr" rid="article-112520.r29">[29]</xref> Other adverse effects with an unknown frequency of BSS include hearing loss or tinnitus, muscle spasms or weaknesses, anxiety, confusion, depression, headaches, and potentially slurred speech.</p>
      </sec>
      <sec id="article-112520.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>In patients with certain medical conditions, bismuth subsalicylate should not be used. BSS should be avoided in:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients undergoing oral treatments for gastric and intestinal conditions with anticoagulants, sulfinpyrazone, probenecid, methotrexate, or any medication with high salicylate concentrations</p>
          </list-item>
          <list-item>
            <p>Patients with gastrointestinal ulceration or hemophilia</p>
          </list-item>
          <list-item>
            <p>Patients with bleeding problems or bloody, black stools before administration of BSS</p>
          </list-item>
          <list-item>
            <p>Children or adolescents with flu-like symptoms: BSS may cause Reye's syndrome in pediatrics or adolescents recovering from influenza or varicella.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients sensitive or allergic to salicylates: In patients who have demonstrated sensitivity toward aspirin, it is advisable not to use bismuth subsalicylate.<xref ref-type="bibr" rid="article-112520.r31">[31]</xref></p>
          </list-item>
        </list>
        <p>For patients with any of the listed conditions, the suggestion is that they use alternative treatment options. Patients should be cautious when using bismuth subsalicylate when traveling to countries where malaria is prevalent, as it can decrease the absorption of doxycycline, an effective antimicrobial for prophylaxis against malaria.<xref ref-type="bibr" rid="article-112520.r5">[5]</xref></p>
      </sec>
      <sec id="article-112520.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Before administering bismuth subsalicylate (BSS), it is recommended that the patient's active medication therapies and history of allergies be assessed. Depending on the patient's medical history, a dose adjustment of BSS or alternate treatment may be necessary. Patients should be counseled on the proper administration of BSS and what to do in cases where diarrhea symptoms persist.</p>
        <p>The therapeutic efficacy of BSS is demonstrated by a reduction in the number of unformed stools and the relief of symptoms. Most patients see a positive therapeutic response within 4 hours of BSS ingestion. BSS toxicity is rare; salicylate plasma concentrations do not need to be monitored.<xref ref-type="bibr" rid="article-112520.r5">[5]</xref> In cases where toxicity is suspected, follow-up monitoring at least 12 hours after the ingestion of salicylate products is recommended.</p>
      </sec>
      <sec id="article-112520.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The most concerning adverse effect of bismuth subsalicylate (BSS) is salicylate toxicity, which can rarely occur. This toxicity primarily occurs in patients who have taken bismuth subsalicylate inappropriately, whether through an overdose or for extended periods.<xref ref-type="bibr" rid="article-112520.r32">[32]</xref> Symptoms of bismuth toxicity include impaired cognition, tremors, lethargy, somnolence, insomnia, delirium, myoclonus, seizures, depressed mood, anxiety, and a depressed mood.<xref ref-type="bibr" rid="article-112520.r33">[33]</xref> If a patient is experiencing bismuth toxicity, they should discontinue BSS use and seek medical attention. There is little evidence to suggest that bismuth subsalicylate can be fatal, although there have been a few reported cases.<xref ref-type="bibr" rid="article-112520.r31">[31]</xref></p>
        <p>Toxicity is generally&#x000a0;reported in patients who ingest more than 150 mg/kg of salicylates (or &#x0003e;6.5 g of aspirin equivalent). There are no specific antidotes for salicylate toxicity. However, managing mild-to-moderate toxicity generally includes supportive care with intravenous fluids. If the patient presents within 2 hours of ingesting BSS, decontamination with activated charcoal is strongly recommended. Salicylate absorption can be delayed; activated charcoal may be&#x000a0;administered beyond 2 hours post-ingestion if the patient is in a normal mental state. Checking the patient's salicylate concentration every 1 to 2 hours is recommended until a decline is observed. The healthcare team should consider urine alkalization if the salicylate concentration exceeds 30 mg/dL.</p>
        <p>In more severe cases and with the presence of altered mental status and metabolic acidosis, hemodialysis may be considered. If the patient cannot maintain their airway and intubation is required, precautions should be taken to avoid severe acidosis. Close follow-up with arterial blood gases and maintaining the pre-intubation minute ventilation and a low PCO<sub>2</sub> level is recommended. Other laboratory parameters recommended to be collected include a hepatic panel, INR/PTT, CBC, electrolytes, and serum creatinine (renal function).</p>
      </sec>
      <sec id="article-112520.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Bismuth subsalicylate (BSS) is an over-the-counter (OTC) product in the United States.<xref ref-type="bibr" rid="article-112520.r28">[28]</xref> Even though this medication is available without a prescription, the interprofessional healthcare team needs to be&#x000a0;aware of the proper use of BSS and coordinate care to educate patients and monitor both efficacy and toxicity.&#x000a0;Pharmacists can identify any drug-drug interactions with BSS and recommend the findings to both providers and patients. Clinicians, nurses, and pharmacists can play a significant role in educating patients about the proper use of BSS and informing the patient about common adverse effects. For example, patients should be aware that the darkening of the stool or tongue using BSS is temporary and harmless. However, patients should contact a healthcare provider before ingesting BSS if they develop a fever or mucus in the stool.</p>
        <p>Patients should discontinue the use of BSS if:</p>
        <list list-type="bullet">
          <list-item>
            <p>Their symptoms last for more than 14 days</p>
          </list-item>
          <list-item>
            <p>Their symptoms worsen</p>
          </list-item>
          <list-item>
            <p>Their diarrhea does not improve after&#x000a0;2 days of use</p>
          </list-item>
          <list-item>
            <p>They develop a fever</p>
          </list-item>
          <list-item>
            <p>They experience hearing loss or tinnitus&#x000a0;<xref ref-type="bibr" rid="article-112520.r17">[17]</xref></p>
          </list-item>
        </list>
        <p>Finally, when toxicity is suspected, a consult with a clinical toxicologist or a poison control center is encouraged to help manage the patient's condition appropriately.</p>
      </sec>
      <sec id="article-112520.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=112520&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=112520">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/112520/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=112520">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-112520.s11">
        <title>References</title>
        <ref id="article-112520.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>AKC</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>AAM</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>AHC</given-names>
              </name>
              <name>
                <surname>Hon</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Travelers' Diarrhea: A Clinical Review.</article-title>
            <source>Recent Pat Inflamm Allergy Drug Discov</source>
            <year>2019</year>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-48</page-range>
            <pub-id pub-id-type="pmid">31084597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koulinska</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Riester</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chalkias</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Effect of Bismuth Subsalicylate on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral Delayed-release Dimethyl Fumarate: PREVENT, a Randomized, Multicenter, Double-blind, Placebo-controlled Study.</article-title>
            <source>Clin Ther</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>12</issue>
            <fpage>2021</fpage>
            <page-range>2021-2030.e1</page-range>
            <pub-id pub-id-type="pmid">30447891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hailey</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Newsom</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of bismuth subsalicylate in relieving symptoms of indigestion.</article-title>
            <source>Arch Intern Med</source>
            <year>1984</year>
            <month>Feb</month>
            <volume>144</volume>
            <issue>2</issue>
            <fpage>269</fpage>
            <page-range>269-72</page-range>
            <pub-id pub-id-type="pmid">6365007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heather</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Travellers' diarrhoea.</article-title>
            <source>BMJ Clin Evid</source>
            <year>2015</year>
            <month>Apr</month>
            <day>30</day>
            <volume>2015</volume>
            <pub-id pub-id-type="pmid">25928418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Oheb</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zaslow</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal Prophylaxis in Sports Medicine.</article-title>
            <source>Sports Health</source>
            <year>2018</year>
            <season>Mar/Apr</season>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>152</fpage>
            <page-range>152-155</page-range>
            <pub-id pub-id-type="pmid">28952896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Boer</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Tytgat</surname>
                <given-names>GN</given-names>
              </name>
            </person-group>
            <article-title>Regular review: treatment of Helicobacter pylori infection.</article-title>
            <source>BMJ</source>
            <year>2000</year>
            <month>Jan</month>
            <day>01</day>
            <volume>320</volume>
            <issue>7226</issue>
            <fpage>31</fpage>
            <page-range>31-4</page-range>
            <pub-id pub-id-type="pmid">10617524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Testerman</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment.</article-title>
            <source>World J Gastroenterol</source>
            <year>2014</year>
            <month>Sep</month>
            <day>28</day>
            <volume>20</volume>
            <issue>36</issue>
            <fpage>12781</fpage>
            <page-range>12781-808</page-range>
            <pub-id pub-id-type="pmid">25278678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miehlke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bayerd&#x000f6;rffer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>DY</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Helicobacter pylori infection.</article-title>
            <source>Semin Gastrointest Dis</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>167</fpage>
            <page-range>167-79</page-range>
            <pub-id pub-id-type="pmid">11478749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chey</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Leontiadis</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Howden</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>112</volume>
            <issue>2</issue>
            <fpage>212</fpage>
            <page-range>212-239</page-range>
            <pub-id pub-id-type="pmid">28071659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rendi-Wagner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kollaritsch</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Drug prophylaxis for travelers' diarrhea.</article-title>
            <source>Clin Infect Dis</source>
            <year>2002</year>
            <month>Mar</month>
            <day>01</day>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>628</fpage>
            <page-range>628-33</page-range>
            <pub-id pub-id-type="pmid">11803509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steffen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Worldwide efficacy of bismuth subsalicylate in the treatment of travelers' diarrhea.</article-title>
            <source>Rev Infect Dis</source>
            <year>1990</year>
            <season>Jan-Feb</season>
            <volume>12 Suppl 1</volume>
            <fpage>S80</fpage>
            <page-range>S80-6</page-range>
            <pub-id pub-id-type="pmid">2406861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ericsson</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Travellers' diarrhoea.</article-title>
            <source>Int J Antimicrob Agents</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>116</fpage>
            <page-range>116-24</page-range>
            <pub-id pub-id-type="pmid">12615374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldman</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Bismuth salicylate for diarrhea in children.</article-title>
            <source>Can Fam Physician</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>59</volume>
            <issue>8</issue>
            <fpage>843</fpage>
            <page-range>843-4</page-range>
            <pub-id pub-id-type="pmid">23946025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Smalley</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Vege</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Carrasco-Labra</surname>
                <given-names>A</given-names>
              </name>
              <collab>Clinical Guidelines Committee</collab>
            </person-group>
            <article-title>American Gastroenterological Association Institute Guideline on the Medical Management of Microscopic Colitis.</article-title>
            <source>Gastroenterology</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>150</volume>
            <issue>1</issue>
            <fpage>242</fpage>
            <page-range>242-6; quiz e17-8</page-range>
            <pub-id pub-id-type="pmid">26584605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitz</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Boissy</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Vinj&#x000e9;</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial activity of bismuth subsalicylate on Clostridium difficile, Escherichia coli O157:H7, norovirus, and other common enteric pathogens.</article-title>
            <source>Gut Microbes</source>
            <year>2015</year>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-100</page-range>
            <pub-id pub-id-type="pmid">25901890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nwokolo</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Mistry</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pounder</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>The absorption of bismuth and salicylate from oral doses of Pepto-Bismol (bismuth salicylate).</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>1990</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-9</page-range>
            <pub-id pub-id-type="pmid">2104082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheele</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cartowski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poddar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stashko</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ravi</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Saccharomyces boulardii and bismuth subsalicylate as low-cost interventions to reduce the duration and severity of cholera.</article-title>
            <source>Pathog Glob Health</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>109</volume>
            <issue>6</issue>
            <fpage>275</fpage>
            <page-range>275-82</page-range>
            <pub-id pub-id-type="pmid">26260354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gorbach</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Bismuth therapy in gastrointestinal diseases.</article-title>
            <source>Gastroenterology</source>
            <year>1990</year>
            <month>Sep</month>
            <volume>99</volume>
            <issue>3</issue>
            <fpage>863</fpage>
            <page-range>863-75</page-range>
            <pub-id pub-id-type="pmid">2199292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walsh</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>The treatment of Helicobacter pylori infection in the management of peptic ulcer disease.</article-title>
            <source>N Engl J Med</source>
            <year>1995</year>
            <month>Oct</month>
            <day>12</day>
            <volume>333</volume>
            <issue>15</issue>
            <fpage>984</fpage>
            <page-range>984-91</page-range>
            <pub-id pub-id-type="pmid">7666920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McNulty</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Bismuth subsalicylate in the treatment of gastritis due to Campylobacter pylori.</article-title>
            <source>Rev Infect Dis</source>
            <year>1990</year>
            <season>Jan-Feb</season>
            <volume>12 Suppl 1</volume>
            <fpage>S94</fpage>
            <page-range>S94-8</page-range>
            <pub-id pub-id-type="pmid">2406863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koletzko</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rowland</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cadranel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Colletti</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Casswall</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Elitsur</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Guarner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalach</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Madrazo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Megraud</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Oderda</surname>
                <given-names>G</given-names>
              </name>
              <collab>H pylori Working Groups of ESPGHAN and NASPGHAN</collab>
            </person-group>
            <article-title>Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children.</article-title>
            <source>J Pediatr Gastroenterol Nutr</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>230</fpage>
            <page-range>230-43</page-range>
            <pub-id pub-id-type="pmid">21558964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Choe</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of two triple eradication regimens in children with Helicobacter pylori infection.</article-title>
            <source>J Korean Med Sci</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>1037</fpage>
            <page-range>1037-40</page-range>
            <pub-id pub-id-type="pmid">17179683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Saleri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tomasoni</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Carosi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Prevention and treatment of traveler's diarrhea. Focus on antimicrobial agents.</article-title>
            <source>Digestion</source>
            <year>2006</year>
            <volume>73 Suppl 1</volume>
            <fpage>109</fpage>
            <page-range>109-18</page-range>
            <pub-id pub-id-type="pmid">16498259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hill</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Ericsson</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Keystone</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Kozarsky</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>DuPont</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Bia</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>ET</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>The practice of travel medicine: guidelines by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2006</year>
            <month>Dec</month>
            <day>15</day>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>1499</fpage>
            <page-range>1499-539</page-range>
            <pub-id pub-id-type="pmid">17109284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riddle</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>DuPont</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Connor</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2016</year>
            <month>May</month>
            <volume>111</volume>
            <issue>5</issue>
            <fpage>602</fpage>
            <page-range>602-22</page-range>
            <pub-id pub-id-type="pmid">27068718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pelepenko</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Janini</surname>
                <given-names>ACP</given-names>
              </name>
              <name>
                <surname>Gomes</surname>
                <given-names>BPFA</given-names>
              </name>
              <name>
                <surname>de-Jesus-Soares</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marciano</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Effects of Bismuth Exposure on the Human Kidney-A Systematic Review.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2022</year>
            <month>Dec</month>
            <day>02</day>
            <volume>11</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">36551397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Weingold</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>The use of gastrointestinal drugs during pregnancy and lactation.</article-title>
            <source>Am J Gastroenterol</source>
            <year>1985</year>
            <month>Nov</month>
            <volume>80</volume>
            <issue>11</issue>
            <fpage>912</fpage>
            <page-range>912-23</page-range>
            <pub-id pub-id-type="pmid">2864852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vilaichone</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Prapitpaiboon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gamnarai</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Namtanee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wongcha-um</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chaithongrat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mahachai</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Seven-Day Bismuth-based Quadruple Therapy as an Initial Treatment for Helicobacter pylori Infection in a High Metronidazole Resistant Area.</article-title>
            <source>Asian Pac J Cancer Prev</source>
            <year>2015</year>
            <volume>16</volume>
            <issue>14</issue>
            <fpage>6089</fpage>
            <page-range>6089-92</page-range>
            <pub-id pub-id-type="pmid">26320500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borbinha</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Serrazina</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Salavisa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Viana-Baptista</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Bismuth encephalopathy- a rare complication of long-standing use of bismuth subsalicylate.</article-title>
            <source>BMC Neurol</source>
            <year>2019</year>
            <month>Aug</month>
            <day>29</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>212</fpage>
            <pub-id pub-id-type="pmid">31464594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sainsbury</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Fatal salicylate toxicity from bismuth subsalicylate.</article-title>
            <source>West J Med</source>
            <year>1991</year>
            <month>Dec</month>
            <volume>155</volume>
            <issue>6</issue>
            <fpage>637</fpage>
            <page-range>637-9</page-range>
            <pub-id pub-id-type="pmid">1812638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aliwalas</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Slaymaker</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Bismuth revisited: an effective way to prevent travelers' diarrhea.</article-title>
            <source>J Travel Med</source>
            <year>2004</year>
            <season>Jul-Aug</season>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>239</fpage>
            <page-range>239-41</page-range>
            <pub-id pub-id-type="pmid">15541227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lambert</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of bismuth-containing compounds.</article-title>
            <source>Rev Infect Dis</source>
            <year>1991</year>
            <season>Jul-Aug</season>
            <volume>13 Suppl 8</volume>
            <fpage>S691</fpage>
            <page-range>S691-5</page-range>
            <pub-id pub-id-type="pmid">1925310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112520.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hogan</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Harbidge</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bismuth Toxicity Presenting as Declining Mobility and Falls.</article-title>
            <source>Can Geriatr J</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>307</fpage>
            <page-range>307-309</page-range>
            <pub-id pub-id-type="pmid">30595782</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
